Medication to alleviate nausea with or without vomiting, vertigo, and pain

Abstract

The technical field that this invention pertains to is pharmaceuticals. The problem that this invention solves is that current over-the-counter migraine / headache medications only treat one symptom which is pain, and current over-the-counter flu products do not address nausea or vomiting which are the most debilitating symptoms of the stomach flu. This invention solves those aforementioned gaps in the market with the addition of an antiemetic to address nausea, vomiting, vertigo, and vestibular symptoms associated with migraines or headaches and the stomach flu. Consumers with migraines or headaches would use this invention if their symptoms included pain, nausea, vomiting, vertigo, or any other vestibular symptoms such as phonophobia or photophobia. Consumers with the stomach flu would use this invention if their symptoms included any of the usual flu symptoms such as fever, pain, body aches, but also with nausea and vomiting which is the key difference compared to existing flu products currently on the market. This invention is new because no prior art discusses using any antiemetics by themselves as a single entity medication or in combination with an analgesic(s) including but not limited to: (1) acetaminophen with or without caffeine and with or without aspirin, (2) acetaminophen with ibuprofen; (3) acetaminophen with naproxen, (4) aspirin, (5) naproxen, and (6) ibuprofen; (7) ketorolac; for the indication of nausea with or without vomiting; vertigo such as migraine-associated vertigo, photophobia, phonophobia, and with or without pain. Additionally, this invention also differs from prior art in that antiemetics can be used in any combination with the aforementioned analgesic(s), and are also able to combined with or without a nasal decongestant such as phenylephrine including any newly reformulated version(s ) of phenylephrine and / or pseudoephedrine with or without dextromethorphan hydrobromide or dextromethorphan polistirex; and with or without guaifenesin. The interchangeability of the drugs and doses allows for versatility which prior art does not offer. Actual dosages used will be within that range at therapeutic, efficacious, and safe dosages in said subjects for the treatment of the indication(s) being claimed and / or exhibited by said subjects at appropriate dosing intervals. Utilizing subtherapeutic and supratherapeutic doses in the ranges are not obvious or usual doses utilized by a person knowledgeable in the prior art, therefore differentiating it from prior art and supporting patentability.

Description

[0001] MEDICATION TO ALLEVIATE NAUSEA WITH OR WITHOUT VOMITING, VERTIGO, AND PAIN

[0002] DESCRIPTION OF THE INVENTION

[0003] The title of this invention is, “Medication to Alleviate Nausea With or Without Vomiting, Vertigo, and Pain.” The technical field to which this invention relates to is pharmaceuticals. This invention solves the problem that there is no over-the-counter medication that treats pain, nausea, vomiting, and vertigo for migraines / headaches and the stomach flu.

[0004] Nausea with or without vomiting, vertigo, and pain are common symptoms associated with many medical conditions. These medical conditions may include viruses such as norovirus or influenza, migraines, headaches, menstrual symptoms, or any condition in which these symptoms may be present. Norovirus causes 19 to 21 million cases each year of acute gastroenteritis in the United States. There were 31 million cases of influenza in the United States and 1 billion worldwide.

[0005] Nausea, vomiting, and pain occur' as major symptoms during menstruation. In comparison with patients who had a regular menstrual cycle, an irregular menstrual cycle increased the incidence of nausea or vomiting from 20.5% to 40.5%.

[0006] Approximately 38 million people in the United States suffer from migraines. About 73% of migraineurs suffer from migraine associated nausea. About 40% of migraineurs suffer from migraine-associated vertigo. The International Classification of Headache Disorders Third Edition (ICHD-3) classifies vestibular migraine Al .6.6. as a distinct disease. The formal classification of vestibular migraine as a recognized disease and its prevalence exemplifies the need for a solution.

[0007] Problems with the prior art is that nausea with or without vomiting, vertigo, and pain are not completely addressed in currently available over-the-counter medications. Some prior art may mention the use of some of the antihistamines or antiemetics used in this invention, but are not specified for nausea with or without the other symptoms for any medical condition(s) in which these symptoms are exhibited.

[0008] This patent addresses coverage of these symptoms; nausea with or without vomiting, vertigo, phonophobia, photophobia, and with or without pain; with or without nasal congestion; with or without cough; with or without chest congestion; for any medical condition(s) that warrants the use of these medications for these symptoms. Consumers should have a comprehensive medication that addresses nausea with or without vomiting, vertigo, and pain and / or any of the aforementioned symptoms for any medical condition(s) in which an antiemetic would be warranted or helpful.

[0009] This invention is different than prior art and is an improvement to prior art in that it allows for the treatment of the singular- symptoms or any combination of symptoms using any combination of the medications in this invention by using them as single entity' medications; such as allowing the usage of diphenhydramine for nausea only, or a combinations) of medications such as diphenhydramine with acetaminophen for nausea and pain; meclizine with any analgesic such as acetaminophen, ibuprofen, or naproxen for example. This patent is different from prior art in that in order to effectively to treat viruses such as influenza or the stomach flu for example, this patent allows any antiemetic such as meclizine, to be combined in any manner with an analgesic, a nasal decongestant such as phenylephrine including any newly reformulated versions of phenylephrine or pseudoephedrine, a cough suppressant such as dextromethorphan hydrobromide or dextromethorphan polistirex, and the expectorant guaifenesin. The reference of combination in any manner refers to the interchangeability of the drugs; such as meclizine with an analgesic and phenylephrine for example, or the combination of an antiemetic such as meclizine with an analgesic and a nasal decongestant and a cough suppressant and an expectorant, which prior art does not address. The best mode to get this product to market is to perform drug formulation and development, including stability testing, to yield a stable product. Additionally, any regulatory’ requirements would be performed to bring this combination drug to market to consumers worldwide.

[0010] This invention contains antihistamines or antiemetics including but not limited to diphenhydramine, meclizine, dimenhydrinate, cyclizine, betahistine, cinnarizine, promethazine; metoclopramide; prochlorperazine; and ondansetron with or without an analgesic(s) including acetaminophen with or without caffeine or aspirin or any combination thereof, acetaminophen as a single entity medication, acetaminophen in combination with ibuprofen, aspirin, ibuprofen, and naproxen, ketorolac; with or without a nasal decongestant phenylephrine or any reformulated version of phenylephrine and pseudoephedrine; with or without a cough suppressant dextromethorphan hydrobromide or dextromethorphan polistirex; with or without a chest decongestant guaifenesin; used interchangeably in different combinations to alleviate symptoms of nausea with or without vomiting, vertigo, photophobia, phonophobia, and pain for any medical condition or disease in which one exhibits these symptoms such as influenza, viruses, headaches, migraines, or menstruation. These examples of medical conditions are not all-inclusive. For instance, if a clinician sees fit to prescribe any combination of these medications in this invention for treatment for any or all the symptoms in this invention, such as post-operation nausea or nausea associated with morning sickness in pregnancy; then this would be allowed or available to treat that particular indication at an appropriate, effective dose for that indication.

[0011] The antihistamines used in this invention have anticholinergic properties which helps prevent nausea and vertigo. Metoclopramide, prochlorperazine and ondansetron are antiemetics. The analgesics in this invention relieve pain. Caffeine enhances the analgesic effect of acetaminophen. Ergot alkaloids treat migraines by constr icting blood vessels, blocking pain signals, and reducing inflammation. Triptans have a vasoconstrictive effect which helps reduce migraine headaches. Magnesium may help treat migraines by blocking brain signals that cause migraines and may also block paintransmitting chemicals in the brain. Phenylephrine and pseudoephedrine are nasal decongestants to relieve stuffy nose or nasal congestion. Dextromethorphan hydrobromide and dextromethorphan polistirex are cough suppressants. Guaifenesin is an expectorant to thin mucous or phlegm in the bronchial passageways.

[0012] The symptoms that are covered in this invention include nausea with or without vomiting, vertigo including migraine-associated vertigo, phonophobia, photophobia, and / or pain; with or without nasal congestion or stuffy nose; with or without cough; with or without chest congestion or mucous in the bronchial passageways. This invention can be used if a person exhibits any or all of these symptoms. For instance, if a person has only nausea, then this invention can be used. If a person has nausea with vertigo, then this product can be used. If a person has nausea with a headache or a migraine, nausea, nasal congestion or stuffy nose, a cough, and chest congestion, or any combination of these symptoms, then this invention can be used. If a person exhibits all multiple symptoms such as pain, nausea and vertigo, this invention or product can be used utilizing any combination(s) of the medications included in the claims or as single entity medications. This invention is not all inclusive for usage or combination of symptoms or medications in that it may be used according to the symptoms exhibited by said subject; for example, if a person has the stomach flu with nausea, headache, fever, nasal congestion, cough, and chest congestion, then all the above aforementioned drugs may be used together to treat those symptoms such as meclizine, acetaminophen, phenylephr ine or pseudoephedrine, dextromethorphan hydrobromide, and guaifenesin. This invention is different and an improvement to prior art in that it allows the first product to treat nausea along with all other possible flu symptoms, because prior art does not include an antiemetic in available multi-symptom flu products. This invention also allows for the addition of vitamins, minerals, natural ingredients, and electrolytes to any interchangeable combination of drugs which is different from prior art and an improvement upon prior art. The ability to incorporate vitamins, minerals, or electrolytes into any of the aforementioned possible drug combinations or separately within the box such as co-packaging them in separate packets or packaging within the drug’s packaging is different from prior art and an improvement upon prior art. This is a major improvement upon prior art especially with the proposed flu product, because there is a loss of electrolytes many times in patients with the stomach flu due to fever, vomiting and diarrhea symptoms, and providing electrolytes either within the actual drug product or packaged separately within the drug’s packaging is convenient for the consumer and provides a complete flu product.

[0013] This invention offers users and / or clinician’s options of usage for different symptoms and combinations of medications. For example, one may use acetaminophen or ibuprofen, or naproxen, or acetaminophen in combination with ibuprofen, acetaminophen in combination with naproxen, in combination with any of the antiemetics listed in this invention. Ibuprofen with meclizine is one example of a possible combination. Acetaminophen with caffeine and aspirin in combination with diphenhydramine is an additional example of how these medications can offer different options of combinations for treatment of these symptoms. The ability to use different combinations of these medications differentiate it from prior art by offering interchangeability as well as the ability’ to treat single symptoms such as nausea and / or the ability to treat a multi-symptom indication such as in migraines in which case, one may exhibit a multitude of symptoms such as pain, nausea, photophobia, phonophobia, and vertigo.

[0014] Diphenhydramine is currently available over-the-counter in the following strengths; (1) Liquid for 12.5mg per 5ml, (2) 12.5mg tablet, (3) 25mg tablet, (4) 50mg tablet. Meclizine is currently available over-the-counter in the following strengths (1) 12.5mg tablet, (2) 25mg tablet, (3) 50mg tablet. Dimenhydrinate is currently available over-the-counter in the following strengths: ( 1) 25mg tablet, and (2) 50mg tablet. Cyclizine is available as 50mg tablets and 50mg injections. Betahistine is available in 8mg and 16mg tablets. Cinnarizine is available in 15mg, 25mg, and 75mg tablets. Promethazine comes in 25mg / ml and 50mg / ml injections, and in 12.5mg, 25mg, and 50mg tablet strengths. Metoclopramide is available as a 5mg / ml injectable form; in 5mg / 5ml and 10mg / 10ml oral solutions; and in 5mg and 10mg tablets. Prochlorperazine is available as injectable in 10mg / 2ml and 50mg / 10ml and comes in 5mg and 10mg tablets; and ondansetron is available in a 4mg / 2ml injectable, a 4mg / 5ml oral solution, and in 4mg, 8mg, and 24mg oral tablets. Cyclizine is dosed at 50mg up to three times a day, up to 200mg / day. Betahistine dose ranges from 24mg to 48mg per day administered two to three times daily. Cinnarizine is dosed at 25mg to 75mg per day in divided doses. Promethazine dosing for nausea and vomiting is 12.5mg to 25mg every four to six hours if needed. Metoclopramide is dosed at 10 to 15mg up to four times a day for nausea. Prochlorperazine is dosed at 5 to 10mg orally every 6 to 8 hours. Ondansetron is dosed at 4mg to 8mg three times a day for nausea and vomiting. The nasal decongestant phenylephrine is dosed at 10mg every four hours as needed not to exceed 60mg in 24 hours and pseudoephedrine is dosed at 60mg every- four to six hours. Dextromethorphan hydrobromide is dosed at 15mg to 30mg three to four times daily and dextromethorphan polistirex is dosed at 10mg to 20mg every four hours as needed or 30mg every six to eight hours as needed. Guaifenesin is an expectorant and is dosed at 200mg to 400mg every four hours and the extended-release formulations contain either 600mg or 1200mg dosed twice daily.

[0015] The available dosage forms may include a liquid form such as a solution or suspension, or a solid oral dosage form such as a capsule, caplet, or tablet, and / or an oral chewable form, orally disintegrating (ODT) tablets, dissolving strip, powder, effervescent powder or tablets, sublingual tablets; transdermal; intravenous; intramuscular; intradermal; subcutaneous; or any form that goes onto or into the skin via a device or patch that can be available either as prescription or nonprescription. The strengths of the active ingredients can vary' in a dosage range that is considered subtherapeutic or supratherapeutic from the current available strengths of each medication according to the strengths that are currently available over-the-counter commercially. For example, diphenhydramine in tablet form is currently available as a 12.5mg tablet / capsule / solution, a 25mg tablet / capsule and a 50mg tablet / capsule. This invention allows for a dosage range utilizing strengths that are below the lowest available strength and above the highest strength commercially available which includes all strengths in-between including current commercially available strengths. In other words, this invention for diphenhydr amine would cover a range of dosage strengths from about 1.25mg to 90mg given at appropriate dosing intervals. These ranges of dosage strengths include subtherapeutic and supratherapeutic dosage strengths which may not be considered usual therapeutic or effective dosage strengths utilized by a person with knowledge in the prior arts. This makes it different from prior art and, therefore patentable because these doses would not be used by a person knowledgeable in the prior ar t. Additionally, the ability to combine the antiemetics, analgesics, nasal decongestants, cough suppressants, and chest decongestant in any combination and interchangeably also makes this patent different from prior art in that prior art does not exist utilizing these possible combinations allowing this patent to treat symptoms and condition(s) accordingly.

[0016] The dosages for the analgesics in this invention are commonly known and listed in literature for the treatment of pain. Ibuprofen is available over-the-counter in a 200mg tablet form and as a liquid suspension. Ibuprofen is commercially available over-the-counter as a 200mg tablet / capsule and a 125mg tablet in combination with acetaminophen 250mg solid oral dosage form. Naproxen is available in a dose of 220mg dose over-the-counter commercially. Ketorolac is available as injection in 15mg / ml and 30mg / mI; as 30mg / ml intramuscular; and in 10mg oral tablets. Acetaminophen is commercially available alone and in combination with caffeine, aspirin; and ibuprofen as a 250mg strength. Acetaminophen is available as a single entity strength in 325mg, 500mg, and 650mg solid oral dosage forms and some liquid formulations. Again, ranges of available strengths for each of these analgesics will allow for doses lower than the lowest available dose commercially available and higher than the highest strength currently available commercially or over-the-counter including all strengths in-between. This invention may be available as an over-the-counter medication or as a prescription medication. For drugs not currently available in the United States, such as cyclizine, betahistine, and cinnarizine, these drugs would follow the guidelines per each country’s governing drug regulations. Dosage guidelines for the allowed drugs in the United States would be per current Food and Drug Administration dosing guidelines for each medication(s) for each indication(s). For example, a normal analgesic dose of acetaminophen is 1 gram every’ 6 hours as needed for pain, not to exceed 4 grams per day as a total daity dose. Therefore, even though the allowable range in this invention covers a range of strengths for acetaminophen from 25mg to 975mg; the proper safe and effective dosage for the treatment of pain would be used for human safety and efficacy.

[0017] Contraindications and precautions and dosages for each indication (i.e., nausea, vertigo, analgesia) for each medication in this invention w ill follow all applicable guidelines and dosages set forth by the Food and Drug Administration for provision of safety and efficacy in humans. The medications should be stored at approximately 20-25 degrees Celsius and avoid humidity. Some products that may require refrigeration w ould be stored at 2-8 degrees Celsius. Labeling would include to keep out of reach of children and close cap tigh tly after each use. This invention will most likely be used in people 12 years of age and older. The chewable and liquid formulations may be beneficial for pediatric populations if studies performed prove beneficial and efficacious for that population, leaving this invention open for usage in the pediatric population per proper, safe and effective dosages. This invention will also contain inactive ingredients such as fillers and other commonly used inactive ingredients in caplet and tablet manufacturing such as gelatin; hydroxypropyl cellulose; titanium dioxide; etc. The aforementioned list are just examples of inactive ingredients that are frequently used in caplet / tablet / capsule formulations and can be commonly found in literature about medication manufacturing. The inactive ingredients commonly used in liquid formulations are listed in literature as well.

[0018] Manufacturing of medications listed in this invention would utilize the tools or manufacturing equipment that is customarily used in the pharmaceutical industry per good manufacturing practices according to Food and Drug Administration guidelines. Drags not currently approved or available in the United States would follow the corresponding country’s drug regulations.

Claims

CLAIMS( 1) A medication to treat or alleviate symptoms, singularly or any combination of symptoms, of nausea, with or without vomiting, vertigo including migraine-associated vertigo, photophobia, phonophobia, and with or without pain associated with any medical condition in which these symptoms are exhibited, comprising any and all of the antihistamines or antiemetics including but not limited to diphenhydramine, meclizine, dimenhydrinate, cyclizine, betahistine, cinnarizine, promethazine, metoclopramide, prochlorperazine, and ondansetron used as single entity or in any combination with the any analgesic(s), prescription or nonprescription, including but not limited to acetaminophen with or without caffeine and with or without aspirin and in any combination thereof such as acetaminophen with aspirin and caffeine or acetaminophen with aspirin or acetaminophen with caffeine or acetaminophen alone as a single entity medication; acetaminophen with ibuprofen; acetaminophen with naproxen; aspirin; ibuprofen; naproxen; ketorolac; comprising of any and all of the antiemetics including, but not limited to: diphenhydramine at a dosage of from about 1 ,25mg to about 90mg; meclizine at a dosage of from about Img to about 95mg; dimenhydrinate at a dosage of from about 2.5mg to about 95mg; cyclizine at a dosage of from about 10mg to about 200mg; betahistine at a dosage of from about 5mg to about 60mg; cinnarizine at a dosage of from about 10mg to about 80mg; promethazine at a dosage of from about 3mg to about 1 OOrng; metoclopramide at a dosage of from about 2mg to about 80mg; prochlorperazine at a dosage of from about 2.5mg to about 80mg; ondansetron at a dosage of from about Img to about 20mg; alone as a single entity or in combination with an analgesic(s) including, but not limited to: acetaminophen at a dosage of from about 25mg to about 975mg as a single entity or in combination with or without aspirin at a dosage of from about 8m g to about 617mg and with or without caffeine at a dosage of from about 6m g to about 190mg and in any combination thereof; acetaminophen at a dosage of from about 25mg to about 975mg in combination with ibuprofen at a dosage of from about 12.5mg to about 800mg; acetaminophen at a dosage of from about 25mg to about 975mg in combination with naproxen at a dosage of from about 22mg to about 1000mg; aspirin at a dosage of from about 8mmg to about 617mg; ibuprofen at a dosage of from about 12.5mg to about 800mg; and naproxen at a dosage of from about 22mg to about 10OOmg; ketorolac at a dosage of from about 2.5mg to about 120mg; with the terminology.“dosage of from about” defined as or referring to the range of a single dose or any single dose within that dosage range given at a single moment of time which will be given at safe and efficacious dosing intervals for the medications utilized such as every 6-8 hours for example, and does not refer in any manner to a range of the total daily dose or dosage.(2) A drug according to claim 1, comprising of the allowable addition of any vitamin(s) and / or mineral(s) including, but not limited to vitamin B2, zinc, and magnesium; natural ingredients including, but not limited to ginger, chamomile, and feverfew; and / or electrolytes which can be incorporated into any dosage form or any combination of drugs according to claim 1 such as an effervescent tablet or oral powder dosage form as examples or packaged separately including co-packaged within the medication packaging in its own individual packets or packaging.(3) A method of treating the symptoms, according to claim 1 , of nausea with or without vomiting; vertigo including migraine-associated vertigo; photophobia; phonophobia; and with or without pain in any medical condition in which these symptoms are exhibited, including but not limited to migraine, headaches, influenza, viruses, menstruation; utilizing the medication(s), comprising any combination of the medications at effective dose(s) per indication( s); administering to a human subject in need thereof, comprising administering to said human subject either as a single entity medication or any combination(s ) thereof of medications.(4) A medication comprising interchangeable combinations of drugs according to claim 1, comprising the different variations and combinations as either single entity medications or interchangeable combinations of claimed medications.(5) A dosage, according to claim 1, comprising an efficacious and safe dose(s) for treatment of the symptoms and / or medical indication(s ) exhibited by said subject.(6) A medication, according to claim I, that can be manufactured in any form(s) such as a solid oral dosage form(s) including tablets of any form including but not limited to orally disintegrating tablets(ODT), gel-tabs, sublingual tablets, chewable tablets, powdered tablets; effervescent powder or tablets, regular compressed tablets, lozenge, a dissolving strip, caplets, capsules, gelcaps, liquid-filled capsules, capsules and / or tablets as immediate release or extended-release formulations; liquid form(s) such as solutions, suspensions including extended-release (long-acting) suspensions, elixirs; powders for any route of administration; oral; intranasal; rectal; intravenous; intramuscular;intradermal; subcutaneous; transdermal; or any form that goes onto (i.e. transdermal patch) or into the skin via a device that can be available either as prescription and / or nonprescription also considered as over- the-counter status.(7) A medication according to claim 1, that can be combined and used interchangeably in any combination with the following medications, utilizing any dosage form and any route of administration: with or without any ergot alkaloid such as dihydroergotamine at a dosage of from about 0.5mg to about 80mg; with or without any triptan or selective serotonin receptor agonist such as sumatriptan at a dosage of from about 10mg to about 400mg; with or without magnesium in any salt form (i.e. magnesium oxide, magnesium sulfate, etc.) at a dosage of from about 100mg to about 4,000mg.(8) A medication to treat or alleviate symptoms, singularly or any combination of symptoms, of nausea, with or without vomiting, vertigo including migraine-associated vertigo, photophobia, phonophobia, and with or without pain, fever, body aches, headache, migraine; with or without nasal congestion or stuffy nose; with or without any type of cough (i.e. productive or nonproductive); with or without chest congestion or mucous secretions also known as phlegm in the bronchial passageways; with or without rhinorrhea commonly called runny nose, associated with any medical conditions ) in which these symptom(s) are exhibited, comprising any and all of the antihistamines or antiemetics including but not limited to diphenhydramine, meclizine, dimenhydrinate, cyclizine, betahistine, cinnarizine, promethazine, metoclopramide; prochlorperazine; and ondansetron used as single entity or in any combination with any analgesic(s), prescription or nonprescription, including but not limited to acetaminophen with or without caffeine and with or without aspirin and in any combination thereof such as acetaminophen with aspirin and caffeine or acetaminophen with aspirin or acetaminophen with caffeine or acetaminophen alone as a single entity medication; acetaminophen with ibuprofen; acetaminophen with naproxen; aspirin; ibuprofen; naproxen; ketorolac; with any and all of the above aforementioned drugs used in any combination with the nasal decongestants pseudoephedrine, phenylephrine including any newly reformulated version of phenylephrine; with or without and in any combination with the cough suppressant dextromethorphan hydrobromide, dextromethorphan polistirex; with or without and in any combination with the chest decongestant or expectorant guaifenesin; comprising ofany and all of the antiemetics: diphenhydramine at a dosage of from about 1.25mg to about 90mg; meclizine at a dosage of from about ling to about 95mg; dimenhydrinate at a dosage of from about 2.5mg to about 95mg; cyclizine at a dosage of from about 10mg to about 200mg; betahistine at a dosage of from about 5mg to about 60mg; cinnarizine at a dosage of from about 10mg to about 80mg; promethazine at a dosage of from about 3mg to about 100mg; metoclopramide at a dosage of from about 2mg to about 80mg; prochlorperazine at a dosage of from about 2.5mg to about 80mg; ondansetron at a dosage of from about Img to about 20mg; alone as a single entity or in combination with any analgesic(s) including, but not limited to: acetaminophen at a dosage of from about 25mg to about 975mg as a single entity' or in combination with or without aspirin at a dosage of from about 8mg to about 617mg and with or without caffeine at a dosage of from about 6mg to about 190mg and in any combination thereof; acetaminophen at a dosage of from about 25mg to about 975mg in combination with ibuprofen at a dosage of from about 12.5mg to about 800mg; acetaminophen at a dosage of from about 25mg to about 975mg in combination with naproxen at a dosage of from about 22mg to about 10OOmg; aspirin at a dosage of from in about 8mg to about 617mg; ibuprofen at a dosage of from about 12.5mg to about 800mg; naproxen at a dosage of from about 22mg to about 10OOmg; ketorolac at a dosage of from about 2.5mg to about 120mg; with or without and in any combination with pseudoephedrine at a dosage of from about 10mg to about 300mg, phenylephrine or any newly reformulated version of phenylephrine at a dosage of from about 10mg to about 60mg; with or without and in any combination with dextromethorphan hydrobromide or any form at a dosage of from about 10mg to about 200mg, dextromethorphan polistirex at a dosage of from about 10mg to about 200mg: with or without and in any combination with guaifenesin at a dosage of from about 5mg to about 3,000mg; with all of the above aforementioned drug(s) used as single entity, used interchangeably, or in any combination with each other to treat or alleviate the symptoms exhibited by said subject; with the terminology, “dosage of from about” defined as or referring to the range of a single dose or any single dose within that dosage range given at a single moment of time which will be given at safe and efficacious dosing intervals for the medications utilized such as every 6-8 hours for example, and does not refer in any manner to a range of the total daily dose or dosage.(9) A drug according to claim 8, comprising of the allowable addition of any vitamin(s ) and / or mineral(s) including, but not limited to vitamin C, zinc, and magnesium; natural ingredients including, but not limited to ginger, chamomile, or feverfew; and / or electrolytes which can be incorporated into any dosage form such as an effervescent tablet or oral powder dosage form as examples or packaged separately including copackaged within the medication packaging in its own individual packets or packaging.(10) A method of treating the symptoms, according to claim 8, of nausea with or without vomiting; vertigo including migraine-associated vertigo; photophobia; phonophobia, sneezing; and with or without pain, body aches, fever, headache, migraine; and with or without nasal congestion or stuffy nose, head congestion, sinus congestion; and with or without cough either productive or nonproductive; and with or without chest congestion causing phlegm or mucous in the bronchial passageways; in any medical condition(s) in which these symptoms are exhibited, including but not limited to migraine, headaches, influenza, stomach flu, viruses, menstruation; pain and body aches, fever, nasal congestion or stuffy nose, sinus congestion, head congestion associated with the flu, hay fever, allergic rhinitis, any allergic condition(s) such as but not limited to allergic sinusitis; common cold; utilizing the medication(s); comprising any combination of the medication(s) for treatment of any combination^ ) of symptoms exhibited at effective dose(s) per indication(s); administering to said subject in need thereof, comprising administering to said subject either as a single entity medication or any combination(s) thereof of medications.(11) A medication comprising interchangeable combinations of drugs according to Claim 8, comprising the different variations and combinations as either single entity medications or interchangeable combinations of claimed medications.(12) A dosage, according to Claim 8, comprising an efficacious and safe dose(s) for treatment of the symptoms and / or medical indication(s) exhibited by said subject.(13) A medication, according to Claim 8, that can be manufactured in any form(s) such as a solid oral dosage form(s) including tablets of any form including but not limited to orally disintegrating tablets(ODT), gel-tabs, sublingual tablets, chewable tablets, powdered tablets; effervescent powder or tablets, regular compressed tablets, lozenge, a dissolving strip, caplets, capsules, gelcaps, liquid-filled capsules, capsules and / or tablets as immediate release or extended-release formulations; liquid form(s) such as solutions,suspensions including extended-release (long-acting) suspensions, elixirs; powders for any route of administration; oral; intranasal; rectal; intravenous; intramuscular; intradermal; subcutaneous; transdermal; or any form that goes onto (i.e. transdermal patch) or into the skin via a device that can be available either as prescription and / or nonprescription also considered as over- the-counter status.